Weekly Analysts’ Ratings Updates for Solid Biosciences (SLDB)

Solid Biosciences (NASDAQ: SLDB) recently received a number of ratings updates from brokerages and research firms:

• 3/25/2026 – Solid Biosciences was upgraded by Truist Financial Corporation to “strong-buy”.
• 3/25/2026 – Solid Biosciences had its price target raised by JPMorgan Chase & Co. from $11.00 to $12.00. They now have an “overweight” rating on the stock.
• 3/23/2026 – Solid Biosciences had its “buy” rating reaffirmed by HC Wainwright. They now have a $20.00 price target on the stock.
• 3/20/2026 – Solid Biosciences is now covered by Guggenheim. They set a “buy” rating and a $26.00 price target on the stock.
• 3/20/2026 – Solid Biosciences had its “buy” rating reaffirmed by Chardan Capital. They now have a $15.00 price target on the stock.
• 3/20/2026 – Solid Biosciences had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $19.00 price target on the stock.
• 3/12/2026 – Solid Biosciences had its “buy” rating reaffirmed by Chardan Capital. They now have a $15.00 price target on the stock.
• 3/11/2026 – Solid Biosciences had its “outperform” rating reaffirmed by Wedbush. They now have a $14.00 price target on the stock.
• 2/9/2026 – Solid Biosciences had its “buy” rating reaffirmed by Needham & Company LLC. They now have a $16.00 price target on the stock.

Insider Activity

In other Solid Biosciences news, CEO Alexander Cumbo sold 80,258 shares of Solid Biosciences stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $6.44, for a total transaction of $516,861.52. Following the completion of the sale, the chief executive officer owned 270,931 shares of the company’s stock, valued at $1,744,795.64. This trade represents a 22.85% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Gabriel Brooks sold 28,335 shares of the business’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $6.44, for a total transaction of $182,477.40. Following the transaction, the insider owned 96,708 shares in the company, valued at approximately $622,799.52. This represents a 22.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 597,672 shares of company stock valued at $3,816,546 in the last three months. 13.63% of the stock is currently owned by insiders.

Solid Biosciences Inc is a clinical‐stage biotechnology company focused on the development of therapies for Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration. The company’s primary approach centers on gene replacement and gene editing technologies designed to restore functional dystrophin protein in patients lacking this critical muscle‐stabilizing protein.

Solid’s lead investigational therapy, SGT‐001, is a micro‐dystrophin gene therapy candidate engineered to deliver a shortened but functional form of the dystrophin gene using an adeno‐associated virus (AAV) vector.